BioCryst Pharmaceuticals
BCRX
100 hedge funds and large institutions have $147M invested in BioCryst Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 32 increasing their positions, 31 reducing their positions, and 21 closing their positions.
323% more call options, than puts
Call options by funds: $262K | Put options by funds: $62K
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
3% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 31
5% less capital invested
Capital invested by funds: $156M → $147M (-$8.54M)
8% less funds holding
Funds holding: 109 → 100 (-9)
43% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 21
Top Buyers
| 1 |
GTC
Ghost Tree Capital
New York
|
+$5.28M |
| 2 |
VMI
VHCP Management II
New York
|
+$3.2M |
| 3 |
VM
VHCP Management
New York
|
+$1.37M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$879K |
| 5 |
RI
RTW Investments
New York
|
+$817K |
Top Sellers
| 1 |
Franklin Resources
San Mateo,
California
|
-$4.69M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.85M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.06M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.54M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.93M |
BCRX Hedge Fund Activity: Q2 2016 in Review
100 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q2 2016, worth a combined $147M — down 5.5% from $156M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of BCRX and 12 opened new positions — a net loss of 9 holders — while 31 trimmed existing stakes and 32 added.
The largest buyer was Ghost Tree Capital, opening a new position worth an estimated $5.28M. The largest seller was Franklin Resources, exiting entirely with an estimated $4.69M sold.
- 100 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q2 2016, down from 109 in Q1 2016.
- Funds reported $147M of BioCryst Pharmaceuticals stock for Q2 2016, down 5.5% quarter-over-quarter.
- 12 funds opened new BioCryst Pharmaceuticals positions in Q2 2016 and 21 closed out, a net change of -9 holders.
- The largest BioCryst Pharmaceuticals buyer in Q2 2016 was Ghost Tree Capital, an estimated $5.28M added.
- The largest BioCryst Pharmaceuticals seller in Q2 2016 was Franklin Resources, an estimated $4.69M sold.
Based on aggregated 13F filings for Q2 2016.